SMRX 11

Drug Profile

SMRX 11

Alternative Names: Clot-buster protein; Clot-specific streptokinase; CSSK; SMRX11

Latest Information Update: 12 Apr 2016

Price : $50

At a glance

  • Originator Institute of Microbial Technology
  • Developer Nostrum Pharmaceuticals
  • Class Coenzymes; Plasminogen activator enzymes; Recombinant fusion proteins; Recombinant proteins; Thrombolytics
  • Mechanism of Action Fibrinolytic agents; Plasmin stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Thrombosis

Most Recent Events

  • 24 Mar 2014 SMRX 11 is still in preclinical trials for thrombosis (IV) in India
  • 10 Mar 2014 Symmetrix Pharmaceuticals plans a phase II trial for Myocardial infarction in India (CTRI/2014/03/004442)
  • 24 Nov 2010 Nostrum Pharmaceuticals acquires additional antithrombotic compounds from the Institute of Microbial Technology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top